The Health Policy Project ended in 2016. Work continued under Health Policy Plus (HP+) until 2022.
PUBLICATION
- Use of Naltrexone in Russia (English)
3,042 kb - Use of Naltrexone in Russia (Russian)
4,101 kb
Author(s): Nicole Judice
Primary Language: English
Date: 9/17/2012
Abstract:
Russia faces significant challenges in diagnosing and treating HIV given the dual epidemic of drug dependence and HIV. In support of the country's efforts, the Health Policy Project assessed the potential for and effectiveness of scaling up naltrexone use. Naltrexone is already approved to treat drug dependence and alcoholism and is on Russia’s essential drugs list. In exploring its use, it appears to be a viable option for pharmaceutical treatment of opiate dependence. Note that other pharmacotherapies are not approved for use in Russia. This situation analysis attempts to identify the perspectives, attitudes, and understanding of practitioners and civil society representatives on how naltrexone use could be used to address HIV and drug dependence in Russia.
HIV People Living With HIV (PLHIV) People who Inject Drugs (PWID) Report Russia
